Research
Hormonal
Bariatric surgery (specifically Roux-en-Y gastric bypass) induces durable weight loss and type 2 diabetes remission through mechanisms beyond simple caloric restriction, including blunted metabolic adaptation, altered gut hormone secretion (increased GLP-1, PYY), and changes in food preference/hedonics.
Bariatric surgery works by changing gut hormones and metabolism, not just by making the stomach smaller. This insight drives the development of non-surgical drugs (like GLP-1 agonists) that mimic these hormonal changes to help with weight loss and diabetes without surgery.
GoodSupportsHIGH confidence
Bariatric surgery is the most effective method for promoting dramatic and durable weight loss in morbidly obese subjects. Furthermore, type 2 diabetes is resolved in over 80% of patients. The mechanisms behind the amelioration in metabolic abnormalities are largely unknown but may be due to changes in energy metabolism, gut peptides and food preference.
Why this rating
Based on a symposium of experts reviewing multiple human and animal studies, though not a single RCT.
Source
Could the mechanisms of bariatric surgery hold the key for novel therapies?: report from a Pennington Scientific Symposium
Charmaine S. Tam et al. · Obesity Reviews · 2011
DOI 10.1111/j.1467-789x.2011.00902.x
narrative_reviewCited 48×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery alters food preference and hedonic response, reducing the appeal of high-calorie, high-sugar foods and increasing preference for low-fat foods, which contributes to sustained weight loss.Good
- Bariatric surgery improves glucose homeostasis and insulin sensitivity through mechanisms involving increased gut hormone secretion (GLP-1, PYY) and altered bile acid metabolism, independent of weight loss in some models.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →